Michelle Dipp, MD PhD is a Co-Founder and Managing Partner of Biospring Partners. She has over a decade of private equity and venture capital expertise in life sciences. Her background in thought leadership and research have been cited over 1000 times on Google Scholar. She currently serves on the Board of Abzena.
Prior to co-founding this new business, Michelle was a Managing Director at General Atlantic, a global growth equity firm based in New York. While at General Atlantic Michelle launched their first life sciences investment platform and served as a member of the life sciences investment committee. Michelle served as a Board Observer for Ginkgo BioWorks and as a board member for PathAI and Immunocore.
“I am a longtime life sciences investor and care deeply about this area, because I know that the technologies we invest in today will shape what healthcare looks like tomorrow. “
“Ruth Bader Ginsberg is one of my role models. She is so strong and poised. One of the things I admire most about her is the relationship she had with her late husband Marty- they were married 35 years.”
Life sciences and technology have converged and the resulting discoveries are redefining medicine as we know it. Artificial intelligence, software and synthetic biology are transforming everything from …